New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareTesamorelin vs Cartalax

Tesamorelin vs Cartalax

Side-by-side comparison of key properties, dosing, and research.

Growth Hormone PeptidesFat Loss & Metabolic
Tesamorelin
Anti-Aging & Longevity
Cartalax
Summary
Tesamorelin is an FDA-approved synthetic GHRH analog specifically indicated for reduction of excess abdominal (visceral) fat in HIV patients with lipodystrophy. It is the only GHRH peptide with FDA approval for a fat-reduction indication and is studied off-label for metabolic syndrome and cognitive function.
Cartalax is a tetrapeptide bioregulator (Ala-Glu-Asp-Pro) developed by Professor Vladimir Khavinson for cartilage and connective tissue. It is tissue-specific for chondrocytes and cartilaginous structures, supporting cartilage matrix synthesis, slowing degenerative changes, and promoting joint longevity. It is used in the context of osteoarthritis, joint aging, and athletic cartilage preservation.
Half-Life
~26 minutes
Short (minutes); gene-regulatory effects are sustained
Admin Route
SubQ
SubQ, Oral
Research
Typical Dose
2 mg
10 mg per day
Frequency
Once daily
Daily for 10–30 days
Key Benefits
  • FDA-approved for visceral fat reduction in HIV lipodystrophy
  • Significant reduction in trunk/visceral fat (average 15–20% in trials)
  • Improved triglyceride and lipid profiles
  • Potential cognitive benefits and memory improvement
  • Preserves lean mass while reducing fat
  • Natural pulsatile GH stimulation
  • Supports cartilage matrix synthesis and maintenance
  • May slow progression of osteoarthritic cartilage degradation
  • Reduces chondrocyte apoptosis
  • Promotes joint longevity in aging and high-impact sports
  • Anti-aging effects on connective tissue
  • Complementary to BPC-157 and TB-500 in joint recovery protocols
  • Well tolerated in available human and animal research
Side Effects
  • Injection site reactions (redness, irritation)
  • Arthralgia and joint pain
  • Peripheral edema
  • Carpal tunnel syndrome
  • +2 more
  • Generally well tolerated
  • Mild injection site reactions
  • No significant adverse events reported at standard doses
Stacks With